Literature DB >> 17332275

Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system.

Frits van Rhee1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17332275     DOI： 10.1158/1078-0432.CCR-06-2650

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  7 in total

1.  The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.

Authors:  Shamaila Munir Ahmad; Evelina Martinenaite; Morten Holmström; Mia Aaboe Jørgensen; Özcan Met; Claudia Nastasi; Uffe Klausen; Marco Donia; Lars Møller Pedersen; Lars Munksgaard; Niels Ødum; Anders Woetmann; Inge Marie Svane; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2017-11-01       Impact factor: 8.110

Review 2.  Immunotherapy of multiple myeloma.

Authors:  Simone A Minnie; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 3.  Immunogenic targets for specific immunotherapy in multiple myeloma.

Authors:  Lu Zhang; Marlies Götz; Susanne Hofmann; Jochen Greiner
Journal:  Clin Dev Immunol       Date:  2012-05-07

4.  Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.

Authors:  Katy J McCann; Rosemary Godeseth; Lindsey Chudley; Ann Mander; Gianfranco Di Genova; Paul Lloyd-Evans; Jonathan P Kerr; Vladimir B Malykh; Matthew W Jenner; Kim H Orchard; Freda K Stevenson; Christian H Ottensmeier
Journal:  Cancer Immunol Immunother       Date:  2015-05-16       Impact factor: 6.968

Review 5.  Boosting Immunity against Multiple Myeloma.

Authors:  Raquel Lopes; Bruna Velosa Ferreira; Joana Caetano; Filipa Barahona; Emilie Arnault Carneiro; Cristina João
Journal:  Cancers (Basel)       Date:  2021-03-11       Impact factor: 6.639

6.  Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens.

Authors:  Selma Bekri; Reunet Rodney-Sandy; Diana Gruenstein; Anna Mei; Bjarne Bogen; John Castle; Daniel Levey; Hearn Jay Cho
Journal:  J Immunother Cancer       Date:  2022-02       Impact factor: 13.751

7.  Trial watch: Dendritic cell-based interventions for cancer therapy.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.